Drug intelligence / Profile preview

Relaxation Active Study Product 2.1

Development stage: Unknown
Lead developer: Radicle Science
Administration: Oral

Overview

Relaxation Active Study Product 2.1 is a dietary supplement studied as part of a randomized, double-blind, placebo-controlled clinical trial (Radicle Relaxation 24) designed to assess its effects on stress and related health outcomes in adults in the United States. The precise formulation and mechanism of action of the product are undisclosed within publicly available clinical trial records. The intervention is targeted at reducing stress, anxiety, and emotional distress, and improving cognitive function and additional well-being markers over a 6-week period. Biomarker monitoring includes changes in stress hormones, inflammatory markers, and mood-related reporting.

Brand names: Relaxation Active Study Product 2.1
Other names: Relaxation Active Study Product 2.1

Beyond the preview

Go deeper on Relaxation Active Study Product 2.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Relaxation Active Study Product 2.1.

Explore the full profile